8-K: Anteris Stockholders Approve Waiver; PARADIGM Trial Delayed

Anteris Technologies Global Corp. stockholders approved an ASX waiver, while patient enrollment for its pivotal PARADIGM Trial is now expected in Q4 2025, a delay from Q3 2025.

Summary

• A special meeting of stockholders was held on September 29, 2025, with 18,687,740 shares, representing approximately 51.8% of outstanding common stock, present.
• Stockholders approved the ASX Waiver Proposal with 13,655,466 votes for, 2,601,191 against, and 2,431,083 abstentions, allowing the company to issue new securities without further stockholder approval under ASX Listing Rule 7.1.
• The Adjournment Proposal was also approved with 13,762,610 votes for, 2,461,912 against, and 2,463,218 abstentions, but was not necessary as the ASX Waiver Proposal passed.
• Patient enrollment for the global pivotal PARADIGM Trial, initially expected in Q3 2025, is now anticipated to commence in Q4 2025.
• The delay in the PARADIGM Trial enrollment is due to an FDA request for additional information, primarily related to bench testing, which the company has since addressed.
• Regulatory submissions for the PARADIGM Trial are also underway with competent authorities in Europe.

Sentiment

Score: 5

Explanation: The approval of the ASX waiver is a positive for future financial flexibility, but the delay in the pivotal PARADIGM Trial enrollment, even with the FDA's request addressed, introduces uncertainty and pushes back a critical milestone. The net effect is neutral to slightly negative due to the trial delay.

Positives

• Stockholders approved the ASX Waiver Proposal, which permits the company to issue new securities without obtaining further stockholder approval under ASX Listing Rule 7.1, streamlining future equity issuance processes.
• The company has successfully addressed the FDA's request for additional information regarding bench testing for the PARADIGM Trial, indicating progress in regulatory compliance.
• Regulatory submissions for the PARADIGM Trial are actively progressing in Europe, demonstrating a commitment to a multi-regional market strategy for the DurAVR THV System.

Negatives

• Patient enrollment for the global pivotal PARADIGM Trial has been delayed from the initially anticipated Q3 2025 to Q4 2025.

Risks

• Delays in critical clinical trials, such as the PARADIGM Trial, can extend development timelines, increase costs, and postpone potential market entry and revenue generation.
• Regulatory bodies like the FDA may request additional information, which can introduce unforeseen delays and require significant resources to address, impacting the overall project schedule.

Future Outlook

Patient enrollment in the global pivotal PARADIGM Trial is now anticipated to commence in the fourth quarter of 2025, following the company's response to the FDA's request for additional information. Regulatory submissions in Europe for the trial are also underway, indicating a continued push for multi-regional market access.

Management Comments

• The company has now addressed the FDA's request for additional information, primarily related to bench testing.
• Regulatory submissions to competent authorities in Europe are underway, highlighting the company's commitment to advancing the PARADIGM Trial across multiple regions.

Industry Context

The medical device industry, particularly for novel cardiovascular technologies like the DurAVR THV System, is characterized by stringent regulatory pathways and lengthy clinical trials. Delays in pivotal trials, while not uncommon, can impact investor sentiment and competitive positioning. The company's proactive engagement with both the FDA and European regulatory bodies reflects a standard, yet complex, global market entry strategy for innovative medical technologies.

Corporate Governance

Stakeholder Impact

• Shareholders: The ASX waiver provides strategic flexibility for future capital raises, which could lead to dilution but also fund growth. The trial delay may impact investor confidence and the timeline for potential revenue generation.
• Patients: The delay in the PARADIGM Trial means a longer wait for potential access to the DurAVR THV System, which could address a significant medical need.
• Regulatory Bodies (FDA, European Authorities): Continued engagement and submission of required information are critical for trial progression and eventual market approval, requiring ongoing resource allocation and compliance.

Next Steps

• Commence patient enrollment in the PARADIGM Trial in Q4 2025.
• Continue regulatory submissions to competent authorities in Europe for the PARADIGM Trial.

Key Dates

Recommendation

While the approval of the ASX waiver provides strategic flexibility for future capital raises, the delay in the pivotal PARADIGM Trial enrollment is a notable setback. The trial's success is critical for the company's long-term value proposition. Investors should hold, awaiting further updates on trial enrollment progress and regulatory milestones, as the delay introduces uncertainty despite the company addressing the FDA's requests.

Keywords

Anteris Technologies, AVR, SEC Filing, 8-K, ASX Waiver, PARADIGM Trial, FDA, Clinical Trial, Medical Device, DurAVR THV System, Stockholder Vote, Regulatory Approval